Stockscreener 앱 받기
26.29
2.18%
0.56
시간 외 거래:
26.29
Pacira Biosciences Inc 주식(PCRX)의 최신 뉴스
Pacira BioSciences (NASDAQ:PCRX) CFO Shawn Cross Sells 15,896 Shares - MarketBeat
Insider Selling: Pacira BioSciences (NASDAQ:PCRX) CFO Sells 9,104 Shares of Stock - MarketBeat
Pacira Biosciences CFO cross sells $626k in shares By Investing.com - Investing.com India
Pacira Biosciences CFO cross sells $626k in shares - Investing.com
Is Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Stock Price Struggling As A Result Of Its Mixed Financials? - 富途牛牛
(PCRX) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Pacira BioSciences (PCRX): Valuation Check After New Iovera Clinical Data and Smart Tip FDA Clearance - Sahm
Barclays Initiates Coverage of Pacira BioSciences (PCRX) with Equal-Weight Recommendation - Nasdaq
Pacira BioSciences (PCRX): Barclays Initiates Coverage with Equa - GuruFocus
Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated by Analysts at Barclays - MarketBeat
102,668 Shares in Pacira BioSciences, Inc. $PCRX Bought by WINTON GROUP Ltd - MarketBeat
PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation - ACCESS Newswire
EV Market: Will Pacira BioSciences Inc. stock maintain momentum in 20252025 Earnings Surprises & Risk Adjusted Swing Trade Ideas - BỘ NỘI VỤ
Will Pacira BioSciences Inc. (82P) stock rise with strong economyQuarterly Trade Report & Real-Time Volume Analysis Alerts - Newser
How Investors Are Reacting To Pacira BioSciences (PCRX) Spine Pain Trial Win And New FDA Clearance - Sahm
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach Out - ACCESS Newswire
Can Pacira BioSciences Inc. (82P) stock surprise with quarterly resultsJuly 2025 Reactions & Daily Profit Focused Stock Screening - Newser
Is Pacira BioSciences Inc. (82P) stock among top earnings plays2025 Fundamental Recap & Free Fast Entry Momentum Trade Alerts - Newser
Can Pacira BioSciences Inc. stock deliver surprise earnings beatWeekly Market Summary & Real-Time Price Movement Reports - Newser
Pacira Biosciences reports inducement grants under Nasdaq Listing Rule - marketscreener.com
Pacira BioSciences (PCRX) Awards Inducement Grants to New Employ - GuruFocus
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Pacira BioSciences (Nasdaq: PCRX) issues 2,200 inducement RSUs to two new employees - Stock Titan
Why Pacira BioSciences Inc. (82P) stock attracts wealthy investorsJuly 2025 Selloffs & Precise Swing Trade Alerts - Newser
Pacira’s iovera° shows better outcomes than RFA for chronic back pain By Investing.com - Investing.com South Africa
Does Pacira’s ioveradeg Pilot Data and Smart Tip Clearance Change The Bull Case For Pacira (PCRX)? - Yahoo Finance
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Pacira’s iovera° shows better outcomes than RFA for chronic back pain - Investing.com Nigeria
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain - Ortho Spine News
Pacira Says Iovera Outperformed Radiofrequency Ablation in Chronic Low Back Pain - marketscreener.com
What macro factors could drive Pacira BioSciences Inc. (82P) stock higherWeekly Stock Recap & Weekly Setup with ROI Potential - Newser
American Century Companies Inc. Has $28.26 Million Stock Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
How risky is Pacira BioSciences Inc. stock now2025 Price Action Summary & Weekly Sector Rotation Insights - BỘ NỘI VỤ
(PCRX) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Pacira BioSciences (PCRX): Valuation in Focus Following Moves to Defend EXPAREL Patents Against Generic Competition - Sahm
Pacira down after FDA filing for generic Exparel - MSN
Pacira BioSciences (PCRX): Assessing Valuation Following Legal Win That Delays EXPAREL Generic Approvals - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect - ACCESS Newswire
Is Pacira’s 30-Month Generic Delay for EXPAREL Shifting the Investment Outlook for PCRX? - Sahm
Pacira BioSciences Inc. Files Patent Infringement Lawsuit, Initiating 30-Month Stay of ANDA Approvals for EXPAREL® - Quiver Quantitative
Pacira BioSciences files Exparel patent infringement lawsuits against the WhiteOak Group and Qilu Pharmaceutical - marketscreener.com
Pacira BioSciences Files EXPAREL® Patent Infringement - GlobeNewswire
What analysts say about Pacira BioSciences Inc 82P stockRetail Trading Trends & Learn the Basics of Investing in 5 Days - earlytimes.in
Is Pacira BioSciences Inc a good long term investmentRSI Overbought/Oversold & Low Entry Investment Ideas - earlytimes.in
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Will Pacira BioSciences Inc. (82P) stock beat Nasdaq index returnsWeekly Trade Report & Low Risk Investment Opportunities - newser.com
Pacira BioSciences, Inc. $PCRX Shares Sold by Bank of Montreal Can - MarketBeat
How to integrate Pacira BioSciences Inc. into portfolio analysis toolsSwing Trade & Reliable Volume Spike Trade Alerts - newser.com
1.48%
0.09%
자본화:
|
볼륨(24시간):